- Conditions
- Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
- Interventions
- Pegylated Interferon alpha-2b, Capecitabine, 5-FU
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 200
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C, Chronic
- Interventions
- Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Kansas City, Kansas • New Orleans, Louisiana + 9 more
- Conditions
- Hepatitis C Virus
- Interventions
- BMS-791325, Placebo, Peg-interferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 10
- States / cities
- Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more
- Conditions
- Hepatitis C Virus Genotype-1
- Interventions
- TMC435, Pegylated interferon alpha-2a, Ribavirin
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 17
- States / cities
- La Jolla, California • Long Beach, California • Sacramento, California + 13 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, RO5024048, danoprevir, ritonavir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 19
- States / cities
- La Jolla, California • Long Beach, California • Sacramento, California + 15 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Danoprevir, Pegasys, Ritonavir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- La Jolla, California • Sacramento, California • San Diego, California + 20 more
- Conditions
- Non-melanomatous Skin Cancer
- Interventions
- PEG-interferon alfa-2a, gefitinib
- Biological · Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Hepatitis C
- Interventions
- CTS-1027, pegylated interferon, Ribavirin, Placebo
- Drug
- Lead sponsor
- Conatus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, Placebo, RO5190591 (Danoprevir)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 18
- States / cities
- La Jolla, California • Sacramento, California • Orlando, Florida + 14 more
- Conditions
- Chronic Hepatitis C Infection, Fatty Liver
- Interventions
- Rosiglitazone and Pegasys/Ribavirin
- Drug
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hepatitis C, Chronic, Cirrhosis
- Interventions
- Telaprevir, Boceprevir, Peg-IFN, Ribavirin
- Drug
- Lead sponsor
- Louis Stokes VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hepatitis C, HIV Infections
- Interventions
- telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
- Drug · Biological
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 11
- States / cities
- Beverly Hills, California • San Diego, California • San Francisco, California + 8 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- VX-222, telaprevir, ribavirin, peginterferon-alfa-2a
- Drug · Biological
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • San Diego, California • Englewood, Colorado + 25 more
- Conditions
- Hepatitis C
- Interventions
- Eltrombopag, Antiviral therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- San Diego, California • New Haven, Connecticut • Honolulu, Hawaii + 3 more
- Conditions
- Healthy Participants
- Interventions
- BMS-986465, Placebo, Pegasys, Famotidine
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 2
- States / cities
- Anaheim, California • Austin, Texas
- Conditions
- Hepatitis C
- Interventions
- Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis C, Chronic
- Interventions
- Autoinjector, Pre-filled syringe
- Device
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Bradenton, Florida • Orlando, Florida + 9 more
- Conditions
- Hepatitis C
- Interventions
- PF-00868554, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 9
- States / cities
- La Jolla, California • San Francisco, California • Orlando, Florida + 5 more
- Conditions
- Hepatitis C Infection
- Interventions
- Placebo, SCY-635, Pegasys, Copegus
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- San Francisco, California • Durham, North Carolina • San Antonio, Texas
- Conditions
- Chronic Hepatitis C Virus Genotype 1
- Interventions
- BMS-824393, Placebo, Peginterferon Alpha-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 11
- States / cities
- Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, peginterferon alfa-2a [Pegasys]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 75 more